Compare Marqeta Inc (MQ) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marqeta Inc vs TG Therapeutics Inc — how do they compare? Marqeta Inc trades at $15.94 (market cap $1.69B), while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). The key difference: TG Therapeutics Inc is far larger — about 5× Marqeta Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Marqeta Inc nearer its low. Which is the better fit depends on your goals.
| MQ | TGTX | |
|---|---|---|
Market Cap | $1.69B | $8.53B |
Sector | Technology | Health |
52-Week High | $23.88 | $59.06 |
52-Week Low | $15.04 | $26.94 |
Enterprise Value | $1.01B | $8.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marqeta (MQ) trades at $16.26, down 1.93% on the day, with a bearish technical signal and neutral oscillators. The company shows improving fundamentals with three consecutive quarterly EPS beats and a return to positive net income projected for 2026. Recent news highlights product expansions with Google and partnerships in stablecoin-backed cards and European markets, signaling growth initiatives.
The stock offers potential upside to the $19 consensus price target, supported by earnings momentum and strategic partnerships. Key risks include high valuation multiples, intense competition in fintech, and reliance on continued execution amid moderating growth expectations in the second half of 2026.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
